v3.19.3.a.u2
CONSOLIDATED BALANCE SHEETS - USD ($)
Oct. 31, 2019
Oct. 31, 2018
Current assets:    
Cash and cash equivalents $ 3,491,625 $ 3,055,890
Short–term investments in certificates of deposit 2,350,000 2,000,000
Receivables 66,527 306,991
Prepaid expenses and other current assets 184,972 175,491
Total current assets 6,093,124 5,538,372
Patents, net of impairment of $1,001,729 and $582,979, respectively, and accumulated amortization of $2,034,381 and $1,615,632, respectively 837,500
Property and equipment, net of accumulated depreciation of $95,015 and $53,799, respectively 200,569 72,670
Total assets 6,293,693 6,448,542
Current liabilities:    
Accounts payable 585,817 582,012
Accrued expenses 895,498 683,099
Total current liabilities 1,481,315 1,265,111
Commitments and contingencies (Note 5)
Shareholders’ equity:    
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding and Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding
Common stock, par value $.01 per share; 48,000,000 shares authorized; 20,331,754 and 18,908,632 shares issued and outstanding, respectively 203,317 189,086
Additional paid-in capital 186,849,299 175,415,931
Accumulated deficit (181,817,263) (170,170,209)
Total shareholders’ equity 5,235,353 5,434,808
Noncontrolling interest (Note 2) (422,975) (251,377)
Total equity 4,812,378 5,183,431
Total liabilities and equity 6,293,693 6,448,542
Series A Preferred Stock [Member]    
Shareholders’ equity:    
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding and Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding
Preferred Stock [Member]    
Shareholders’ equity:    
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding and Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding

Source

v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Revenue $ 250,000 $ 1,112,500
Operating costs and expenses:    
Inventor royalties, contingent legal fees, litigation and licensing expenses 166,250 768,410
Amortization of patents 418,750 325,296
Research and development expenses (including non-cash share based compensation expenses of $2,825,630 and $4,596,866, respectively) 5,473,427 6,813,043
General and administrative expenses (including non-cash share based compensation expenses of $2,888,115 and $4,298,748 respectively) 5,662,828 6,911,830
Impairment in carrying amount of patent assets (Note 2) 418,750 582,979
Total operating costs and expenses 12,140,005 15,401,558
Loss from operations (11,890,005) (14,289,058)
Interest income 71,353 45,974
Loss before income taxes (11,818,652) (14,243,084)
Provision for income taxes (Note 6)
Net loss (11,818,652) (14,243,084)
Less: Net loss attributable to noncontrolling interest (171,598) (247,059)
Net loss attributable to common stockholders $ (11,647,054) $ (13,996,025)
Net loss per share:    
Basic and diluted (in Dollars per share) $ (0.59) $ (0.79)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 19,789,795 17,624,335

Source

v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Cash flows from operating activities:    
Net loss $ (11,818,652) $ (14,243,084)
Stock option compensation to employees and directors 3,560,883 5,717,651
Stock options and warrants issued to consultants 198,421 318,139
Restricted stock award compensation to employee pursuant to stock incentive plan 1,954,441 2,859,824
Common stock issued to consultants 15,002
Amortization of patents 418,750 325,296
Depreciation of property and equipment 47,558 18,435
Impairment in carrying amount of patent assets 418,750 582,979
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee 64,656
Change in operating assets and liabilities:    
Receivables 271,700 (258,991)
Prepaid expenses and other current assets (9,481) (48,925)
Accounts payable 3,805 101,688
Accrued expenses 212,399 273,930
Net cash used in operating activities (4,741,426) (4,273,400)
Cash flows from investing activities:    
Disbursements to acquire short-term investments in certificates of deposit (3,850,000) (4,250,000)
Proceeds from maturities of short-term investments in certificates of deposit 3,500,000 5,750,000
Purchase of property and equipment (175,457) (38,404)
Net cash (used in) provided by investing activities (525,457) 1,461,596
Cash flows from financing activities:    
Proceeds from sale of common stock in at-the-market offering 5,527,428 2,470,182
Proceeds from sale of common stock pursuant to employee stock purchase plan 39,086
Proceeds from settlement of shareholder derivative complaint 14,034
Proceeds from exercise of stock options and warrants 122,070 58,138
Net cash provided by financing activities 5,702,618 2,528,320
Net increase (decrease) in cash and cash equivalents 435,735 (283,484)
Cash and cash equivalents at beginning of year 3,055,890 3,339,374
Cash and cash equivalents at end of year 3,491,625 3,055,890
Supplemental cash flow information:    
Cash proceeds from interest income 55,729 12,684
Supplemental disclosure of non-cash investing activity:    
Disposal of fully depreciated property and equipment (6,343)
Supplemental disclosure of non-cash financing activity:    
Note receivable issued for settlement of shareholder derivative complaint $ 31,236

Source